Bicara Therapeutics Inc. Investment Income, Interest
Bicara Therapeutics Inc. (BCAX) reported Investment Income, Interest of $4.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Bicara Therapeutics Inc. investment income, interest for the quarter ending 2026-06-30 was $4.58M, a 2.26% decline year-over-year.
- Bicara Therapeutics Inc. investment income, interest for the quarter ending 2026-03-31 was $4.08M, a 18.57% decline year-over-year.
- Bicara Therapeutics Inc. investment income, interest for the quarter ending 2025-12-31 was $3.79M, a 35.41% decline year-over-year.
- Bicara Therapeutics Inc. investment income, interest for the quarter ending 2025-09-30 was $4.39M, a 39.37% increase year-over-year.
- Bicara Therapeutics Inc. investment income, interest for fiscal 2025 was $17.87M, a 22.56% increase from fiscal 2024.
- Bicara Therapeutics Inc. investment income, interest for fiscal 2024 was $14.58M, a 1009.67% increase from fiscal 2023.
- Bicara Therapeutics Inc. investment income, interest for fiscal 2023 was $1.31M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.58M 10-Q · filed 2026-08-11 | $8.66M 10-Q · filed 2026-08-11 | $12.45M derived: sum of 3 quarters · filed 2026-08-11 | $16.83M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.08M 10-Q · filed 2026-05-11 | $7.87M derived: sum of 2 quarters · filed 2026-05-11 | $12.26M derived: sum of 3 quarters · filed 2026-05-11 | $16.94M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.18M derived: sum of 2 quarters · filed 2026-03-30 | $12.86M derived: sum of 3 quarters · filed 2026-08-11 | $17.87M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.39M 10-Q · filed 2025-11-10 | $9.07M derived: sum of 2 quarters · filed 2026-08-11 | $14.08M 10-Q · filed 2025-11-10 | $19.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.68M 10-Q · filed 2026-08-11 | $9.70M 10-Q · filed 2026-08-11 | $15.56M derived: sum of 3 quarters · filed 2026-08-11 | $18.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.01M 10-Q · filed 2026-05-11 | $10.88M derived: sum of 2 quarters · filed 2026-05-11 | $14.03M derived: sum of 3 quarters · filed 2026-05-11 | $16.73M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $9.01M derived: sum of 2 quarters · filed 2026-03-30 | $11.71M derived: sum of 3 quarters · filed 2026-03-30 | $14.58M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.15M 10-Q · filed 2025-11-10 | $5.85M derived: sum of 2 quarters · filed 2025-11-10 | $8.71M 10-Q · filed 2025-11-10 | $10.02M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.70M 10-Q · filed 2025-08-12 | $5.57M 10-Q · filed 2025-08-12 | $6.87M derived: sum of 3 quarters · filed 2025-08-12 | $6.88M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.87M 10-Q · filed 2025-05-13 | $4.17M derived: sum of 2 quarters · filed 2025-05-13 | $4.18M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.31M derived: sum of 2 quarters · filed 2025-03-27 | $1.31M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $13.00K 10-Q · filed 2024-11-12 | $13.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |